Dorothy Engelking, M.S.

Vice President, Regulatory Affairs

Dorothy Engelking, M.S., joined DURECT in March 2022 bringing more than 25 years of Regulatory Affairs experience with multiple successful New Drug Application (NDA) and Marketing Authorization Application (MAA) filings. Prior to joining us, Ms. Engelking served as Vice President of Regulatory Affairs, Quality Assurance, and Pharmacovigilance at Adamas Pharmaceuticals from January 2019 to December 2021 where she successfully negotiated an expanded label indication for their lead product. She has held previous positions with Neos Therapeutics as Vice President of Regulatory Affairs, Kendle International as Vice President of Global Regulatory Affairs, Xanodyne Pharmaceuticals as Senior Vice President of Regulatory Affairs, and at Watson Pharmaceuticals (now Allergan) as Vice President of Regulatory Affairs. She received her Bachelor of Science in chemistry and Master of Science in analytical chemistry from South Dakota School of Mines and Technology.

Scroll to Top